Compare Dollar General Corp. (DG) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Nuwellis Inc — how do they compare? Dollar General Corp. trades at $119.27 (market cap $26.50B), while Nuwellis Inc trades at $3.15 (market cap $1.17M). The key difference: Dollar General Corp. is far larger — about 22649.6× Nuwellis Inc's market cap, and Dollar General Corp. pays a 1.96% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| DG | NUWE | |
|---|---|---|
Market Cap | $26.50B | $1.17M |
Sector | Consumer Staples | Technology |
52-Week High | $156.26 | $558.26 |
52-Week Low | $95.94 | $2.80 |
Enterprise Value | $40.95B | -$636.97K |
Dividend Yield | 1.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $123.44, up 3.8% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.00 exceeding expectations of $1.89. Revenue growth continues at $40.61B for 2025, while profit margins face pressure at 3.63%. Recent news highlights the company's back-to-school initiatives and margin expansion efforts.
The outlook remains positive with a $128.45 consensus price target representing 4% upside. Key opportunities include continued same-store sales growth and margin recovery, while risks involve consumer spending sensitivity and competitive pressures in discount retail. The technical setup suggests near-term resistance around $125-$128 levels.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
